Purdue Transdermal Technologies

Purdue Transdermal Technologies was a specialized subsidiary of Purdue Pharma focused on the development and commercialization of transdermal drug delivery systems. The company is best known for its work on Butrans (buprenorphine), a transdermal patch used for the management of chronic pain. As a part of the broader Purdue Pharma organization, the entity has been involved in the extensive litigation and subsequent bankruptcy proceedings related to the opioid crisis. The company's assets and operations are being transitioned into Knoa Pharma, a public benefit corporation, as part of a court-approved restructuring plan. Its core expertise lies in the formulation of small molecule drugs into adhesive patch formats for sustained systemic delivery.